These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 20613963)

  • 1. Regulation of ENaC-Mediated Sodium Reabsorption by Peroxisome Proliferator-Activated Receptors.
    Pavlov TS; Imig JD; Staruschenko A
    PPAR Res; 2010; 2010():703735. PubMed ID: 20613963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peroxisome proliferator-activated receptor gamma antagonists decrease Na+ transport via the epithelial Na+ channel.
    Pavlov TS; Levchenko V; Karpushev AV; Vandewalle A; Staruschenko A
    Mol Pharmacol; 2009 Dec; 76(6):1333-40. PubMed ID: 19752200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New insights into the role of serum- and glucocorticoid-inducible kinase SGK1 in the regulation of renal function and blood pressure.
    Vallon V; Lang F
    Curr Opin Nephrol Hypertens; 2005 Jan; 14(1):59-66. PubMed ID: 15586017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stimulation of ENaC activity by rosiglitazone is PPARγ-dependent and correlates with SGK1 expression increase.
    Renauld S; Tremblay K; Ait-Benichou S; Simoneau-Roy M; Garneau H; Staub O; Chraïbi A
    J Membr Biol; 2010 Aug; 236(3):259-70. PubMed ID: 20740360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PPARγ-induced stimulation of amiloride-sensitive sodium current in renal collecting duct principal cells is serum and insulin dependent.
    Chraïbi A; Renauld S
    Cell Physiol Biochem; 2014; 33(3):581-93. PubMed ID: 24603133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PPARgamma activation enhances cell surface ENaCalpha via up-regulation of SGK1 in human collecting duct cells.
    Hong G; Lockhart A; Davis B; Rahmoune H; Baker S; Ye L; Thompson P; Shou Y; O'Shaughnessy K; Ronco P; Brown J
    FASEB J; 2003 Oct; 17(13):1966-8. PubMed ID: 12923071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peroxisome proliferator-activated receptor-γ agonists repress epithelial sodium channel expression in the kidney.
    Borsting E; Cheng VP; Glass CK; Vallon V; Cunard R
    Am J Physiol Renal Physiol; 2012 Mar; 302(5):F540-51. PubMed ID: 22169011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption.
    Guan Y; Hao C; Cha DR; Rao R; Lu W; Kohan DE; Magnuson MA; Redha R; Zhang Y; Breyer MD
    Nat Med; 2005 Aug; 11(8):861-6. PubMed ID: 16007095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thiazolidinediones and Edema: Recent Advances in the Pathogenesis of Thiazolidinediones-Induced Renal Sodium Retention.
    Horita S; Nakamura M; Satoh N; Suzuki M; Seki G
    PPAR Res; 2015; 2015():646423. PubMed ID: 26074951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PPARgamma agonists do not directly enhance basal or insulin-stimulated Na(+) transport via the epithelial Na(+) channel.
    Nofziger C; Chen L; Shane MA; Smith CD; Brown KK; Blazer-Yost BL
    Pflugers Arch; 2005 Dec; 451(3):445-53. PubMed ID: 16170524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thiazolidinedione-induced fluid retention: recent insights into the molecular mechanisms.
    Bełtowski J; Rachańczyk J; Włodarczyk M
    PPAR Res; 2013; 2013():628628. PubMed ID: 23577024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PPARγ agonist-induced fluid retention depends on αENaC expression in connecting tubules.
    Fu Y; Gerasimova M; Batz F; Kuczkowski A; Alam Y; Sanders PW; Ronzaud C; Hummler E; Vallon V
    Nephron; 2015; 129(1):68-74. PubMed ID: 25531136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GI262570, a peroxisome proliferator-activated receptor {gamma} agonist, changes electrolytes and water reabsorption from the distal nephron in rats.
    Chen L; Yang B; McNulty JA; Clifton LG; Binz JG; Grimes AM; Strum JC; Harrington WW; Chen Z; Balon TW; Stimpson SA; Brown KK
    J Pharmacol Exp Ther; 2005 Feb; 312(2):718-25. PubMed ID: 15475592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of the serum and glucocorticoid-inducible kinase SGK1 attenuates the volume retention after treatment with the PPARgamma agonist pioglitazone.
    Artunc F; Sandulache D; Nasir O; Boini KM; Friedrich B; Beier N; Dicks E; Pötzsch S; Klingel K; Amann K; Blazer-Yost BL; Scholz W; Risler T; Kuhl D; Lang F
    Pflugers Arch; 2008 May; 456(2):425-36. PubMed ID: 18172605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of renal proximal tubule transport in thiazolidinedione-induced volume expansion.
    Seki G; Endo Y; Suzuki M; Yamada H; Horita S; Fujita T
    World J Nephrol; 2012 Oct; 1(5):146-50. PubMed ID: 24175252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitors of the proteasome stimulate the epithelial sodium channel (ENaC) through SGK1 and mimic the effect of aldosterone.
    Mansley MK; Korbmacher C; Bertog M
    Pflugers Arch; 2018 Feb; 470(2):295-304. PubMed ID: 28861610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of peroxisome proliferator-activated receptor gamma agonists on Na+ transport and activity of the kinase SGK1 in epithelial cells from lung and kidney.
    Wilson SM; Mansley MK; Getty J; Husband EM; Inglis SK; Hansen MK
    Br J Pharmacol; 2010 Feb; 159(3):678-88. PubMed ID: 20105179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thiazolidinedione-induced fluid retention is independent of collecting duct alphaENaC activity.
    Vallon V; Hummler E; Rieg T; Pochynyuk O; Bugaj V; Schroth J; Dechenes G; Rossier B; Cunard R; Stockand J
    J Am Soc Nephrol; 2009 Apr; 20(4):721-9. PubMed ID: 19158355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Time course of AQP-2 and ENaC regulation in the kidney in response to PPAR agonists associated with marked edema in rats.
    Tiwari S; Blasi ER; Heyen JR; McHarg AD; Ecelbarger CM
    Pharmacol Res; 2008 May; 57(5):383-92. PubMed ID: 18468451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease.
    Guan Y; Breyer MD
    Kidney Int; 2001 Jul; 60(1):14-30. PubMed ID: 11422732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.